NCT02770014

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patient with Non-Small Cell Lung Cancer (NSCLC) that might have a genetic change (mutation) in the Epidermal Growth Factor Receptor (EGFR) are invited to take part in this study. This research study is evaluating a new blood test that is capable of detecting an EGFR mutation in cancer without a biopsy.

Detailed description

This research study is a Phase II clinical trial. This research study will determine if a rapid blood test can be used to detect EGFR mutations in patients with newly diagnosed lung cancer and use that information to rapidly start patients on a pill-based therapy. This blood test has not previously been used to select patients for treatment with Erlotinib without confirming this finding on a biopsy.

Conditions

• Epidermal Growth Factor Receptor
• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Erlotinib

Timeline

• Start date: 2016-06-01
• Primary completion: 2019-04-16
• Completion: 2019-06-19
• First posted: 2016-05-12
• Last updated: 2019-11-22
• Results posted: 2019-11-22

Locations

3 sites across 1 country: United States